Toxicity and Survival for Metastatic Melanoma Patients Treated With Anti-PD1 Therapy and Radiation Treatment

被引：1
|
作者：
Mowery, Y. M. [1 ]
Patel, K. [2 ]
Olson, A. C. [1 ]
Khan, M. K. [2 ]
Salama, J. K. [1 ]
Salama, A. K. [1 ]
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
[2] Emory Univ, Winship Canc Inst, Dept Radiat Oncol, Atlanta, GA 30322 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2016年 / 96卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2016.06.383
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
357
引用
下载
收藏
页码：S158 / S159
页数：2
相关论文
共 50 条
  • [21] Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
    Joseph, Richard W.
    Cappel, Mark
    Goedjen, Brent
    Gordon, Matthew
    Kirsch, Brandon
    Gilstrap, Cheryl
    Bagaria, Sanjay
    Jambusaria-Pahlajani, Anokhi
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (01) : 18 - 22
  • [22] Anti-PD1 therapy and CD8 T cell invigoration in metastatic melanoma
    Huang, Alexander
    Xu, Wei
    Harmon, Shannon
    Quagliarello, Felix
    Herati, Ramin
    Pauken, Kristen
    Bengsch, Bertram
    Schuchter, Lynn
    Amaravadi, Ravi
    McGettigan, Suzanne
    Gangadhar, Tara
    Wherry, John
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
  • [23] Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma previously treated with anti-PD1 therapy
    Sullivan, Ryan J.
    Moschos, Stergios J.
    Johnson, Melissa L.
    Opyrchal, Mateusz
    Ordentlich, Peter
    Brouwer, Susan
    Sankoh, Serap
    Meyers, Michael L.
    Agarwala, Sanjiv S.
    CANCER RESEARCH, 2019, 79 (13)
  • [24] Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy
    Amato, Carol M.
    Hintzsche, Jennifer D.
    Wells, Keith
    Applegate, Allison
    Gorden, Nicholas T.
    Vorwald, Victoria M.
    Tobin, Richard P.
    Nassar, Kelsey
    Shellman, Yiqun G.
    Kim, Jihye
    Medina, Theresa M.
    Rioth, Matthew
    Lewis, Karl D.
    McCarter, Martin D.
    Gonzalez, Rene
    Tan, Aik-Choon
    Robinson, William A.
    CANCERS, 2020, 12 (07) : 1 - 15
  • [25] PERFORMANCE STATUS AS A PREDICTOR OF RESPONSE TO ANTI-PD1 FOR METASTATIC MELANOMA
    Wong, A.
    Williams, M.
    Milne, D.
    Morris, K.
    Lau, P.
    Spruyt, O.
    Fullerton, S.
    McArthur, G.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 71 - 71
  • [26] Metastatic site and response to pembrolizumab (anti-PD1 antibody) in melanoma
    Tumeh, Paul Camille
    Rosenblum, Michael
    Handley, Nathan
    Tsai, Katy
    Rodriguez, Robert S. Rodriguez
    Khurana, Niharika
    Harview, Christina
    Spasic, Marko
    Sanchez, Phillip J.
    Chang, Jeremy
    Shintaku, I. Peter
    Taylor, Emma
    Chmielowski, Bartosz
    Grogan, Tristan
    Elashoff, David A.
    Pierce, Robert H.
    Daud, Adil
    CANCER RESEARCH, 2015, 75
  • [27] Change of laboratory parameters during anti-PD1 treatment in patients with melanoma
    Janka, E. A.
    Vanyai, B.
    Varvolgyi, T.
    Remenyik, E.
    Emri, G.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (09) : S303 - S303
  • [28] Purple papules during anti-PD1 immunotherapy for metastatic melanoma
    De Luca, Erika V.
    Catapano, Silvia
    Del Regno, Laura
    Di Stefani, Alessandro
    Peris, Ketty
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 (04): : 630 - 632
  • [29] Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
    Paoluzzi, L.
    Cacavio, A.
    Ghesani, M.
    Karambelkar, A.
    Rapkiewicz, A.
    Weber, J.
    Rosen, G.
    CLINICAL SARCOMA RESEARCH, 2016, 6
  • [30] Analysis of circulating tumor DNA (ctDNA) in pseudoprogression in anti-PD1 treated metastatic melanoma (MM).
    Lee, Jenny H. J.
    Long, Georgina V.
    Menzies, Alexander M.
    Gunninski, Alexander David
    Kefford, Richard
    Rizos, Helen
    Carlino, Matteo S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345